- HaluGen Life Sciences, a subsidiary of Entheon Biomedical (ENBI), has announced that its Psychedelics Genetic Test Kit is now available for sale in the United States
- The test kit evaluates an individual’s overall sensitivity and risk profile associated with psychedelic-assisted therapy
- It provides users with personalized reports and actionable insights delivered directly to a user’s smartphone or desktop
- Entheon is a biotechnology research and development company
- Entheon Biomedical Corp. (ENBI) is up 1.01 per cent, trading at $0.50 per share
Entheon Biomedical (ENBI) subsidiary HaluGen Life Sciences has announced that its Psychedelics Genetic Test Kit is now available for sale in the US.
The test kit evaluates an individual’s overall sensitivity and risk profile associated with psychedelic-assisted therapy.
It provides users with personalized reports and actionable insights delivered directly to a user’s smartphone or desktop through the HaluGen website.
Timothy Ko, CEO of Entheon, commented on the launch of HaluGen’s test kit.
“The launch of this kit into the US market is a significant milestone for the company,” he remarked, “and one that is sure to drive awareness of HaluGen’s Test Kit and the overall potential of personalized tools for use in preparation of psychedelic treatment.”
Genetics can play a key role in determining how an individual may respond to psychedelic-assisted psychotherapy.
By obtaining DNA test results and data from mental-health surveys, individuals are equipped with valuable insights to make more informed decisions around psychedelic-assisted therapy, potential side effects and risk profile.
Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine-based psychedelic therapeutic products to treat addiction and substance use disorders.
Entheon Biomedical Corp. (ENBI) is up 1.01 per cent, trading at $0.50 per share as of 12:42 pm.